Infliximab in graft-versus-host disease

Successful Treatment of Von Zumbusch Pustular Psoriasis with Infliximab

“…2,3 Since its arrival, numerous other off-label uses have been discovered, such as psoriasis vulgaris, psoriatic arthritis, pyoderma gangrenosum, hidradenitis suppurativa, subcorneal pustular dermatosis, Behcet's disease, toxic epidermal necrolysis, sarcoidosis, and graft-versus-host disease. [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] Three case reports, one of which was from our institution, have been published in the literature advocating the use of infliximab for pustular psoriasis. 24,25 Patient 1 in this study had been previously reported in the literature.…”

Lichenoid variant of chronic cutaneous graft versus host reaction post blood transfusion: A rare event post blood transfusion

“…PUVA photochemotherapy and narrow-band UVB phototherapy are other options for skin involvement, while extracorporeal photochemotherapy may improve cutaneous as well as systemic involvement[ 1 8 ]. Granulocyte colony-stimulating factor,[ 25 ] antilymphocyte globulin,[ 26 ] tacrolimus,[ 27 ] biological therapies,[ 28 ] including etanercept,[ 29 ] and particularly rituximab,[ 30 ] may be helpful for steroid-resistant disease.…”

Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival

“…TNF-α is significantly increased in patients with aGVHD [7], and inhibition of TNFα may potentially control aGVHD [8]. Inhibition of TNF-α has been suggested in all phases of aGvHD treatment; as prevention [9,10], as part of primary aGvHD treatment [11][12][13][14][15], and most commonly as treatment for steroid-refractory or steroid-dependent aGVHD [16][17][18][19][20][21][22][23][24][25].…”